#### 1 Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100

### 2 health facilities throughout Tanzania: February to July 2021

- 3
- 4 Eric Rogier<sup>1</sup>, Nastassia Battle<sup>2</sup>, Catherine Bakari<sup>3</sup>, Misago D. Seth<sup>3</sup>, Douglas Nace<sup>1</sup>, Camelia
- 5 Herman<sup>1</sup>, Rashid A. Madebe<sup>3</sup>, Celine I. Mandara<sup>3</sup>, Beatus M. Lyimo<sup>3,4</sup>, David J. Giesbrecht<sup>5</sup>,
- <sup>6</sup> Zachary R. Popkin-Hall<sup>6</sup>, Filbert Francis<sup>7</sup>, Daniel Mbwambo<sup>8</sup>, Issa Garimo<sup>8</sup>, Sijenunu Aaron<sup>8</sup>,
- 7 Abdallah Lusasi<sup>8</sup>, Fabrizio Molteni<sup>9</sup>, Ritha Njau<sup>10</sup>, Jane A. Cunningham<sup>11</sup>, Samwel Lazaro<sup>8</sup>, Ally
- 8 Mohamed<sup>8</sup>, Jonathan J. Juliano<sup>6</sup>, Jeffrey A. Bailey<sup>5</sup>, Venkatachalam Udhayakumar<sup>1</sup>, Deus S.
- 9 Ishengoma<sup>3,12,13</sup>
- 10
- <sup>1</sup>Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- 12 <sup>2</sup>CDC Foundation, Atlanta, GA
- <sup>3</sup>National Institute for Medical Research, Dar es Salaam, Tanzania.
- 14 <sup>4</sup>Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania
- 15 <sup>5</sup>Brown University, Providence, MA, USA
- <sup>6</sup>University of North Carolina, Chapel Hill, NC, USA
- 17 <sup>7</sup>National Institute for Medical Research, Tanga, Tanzania
- 18 <sup>8</sup>National Malaria Control Programme, Dodoma, Tanzania
- 19 <sup>9</sup>Swiss Tropical Public Health Institute, Dar es Salaam, Tanzania
- 20 <sup>10</sup>World Health Organization, Country Office, Dar es Salaam, Tanzania
- 21 <sup>11</sup>World Health Organization, Headquarters, Geneva, Switzerland
- 22 <sup>12</sup>Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia
- 23 <sup>13</sup>Harvard T.H Chan School of Public Health, Boston, MA, USA
- 24
- 25 **Correspondence**: Eric Rogier, Centers for Disease Control and Prevention, Atlanta, GA 30029.
- 26 erogier@cdc.gov
- 27
- 28
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 29 Abstract

30 Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome 31 can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health 32 Organization (WHO) recommends switching to a non-HRP2 RDT for P. falciparum clinical case 33 diagnosis when *pfhrp2* deletion prevalence causes  $\geq$  5% of RDTs to return false negative 34 results. Tanzania is a country of heterogenous P. falciparum transmission, with some regions 35 approaching elimination and others at varying levels of control. In concordance with the current recommended WHO pfhrp2 deletion surveillance strategy, 100 health facilities encompassing 36 37 10 regions of Tanzania enrolled malaria-suspected patients between February and July 2021. Of 7,863 persons of all ages enrolled and providing RDT result and blood sample, 3,777 38 39 (48.0%) were positive by the national RDT testing for *Plasmodium* lactate dehydrogenase 40 (pLDH) and/or HRP2. A second RDT testing specifically for the *P. falciparum* LDH (Pf-pLDH) 41 antigen found 95 persons (2.5% of all RDT positives) were positive, though negative by the 42 national RDT for HRP2, and were selected for *pfhrp2* and *pfhrp3* (*pfhrp2/3*) genotyping. 43 Multiplex antigen detection by laboratory bead assay found 135/7,847 (1.7%) of all blood 44 samples positive for *Plasmodium* antigens but very low or no HRP2, and these were selected 45 for genotyping as well. Of the samples selected for genotyping based on RDT or laboratory 46 multiplex result, 158 were P. falciparum DNA positive, and 140 had sufficient DNA to be 47 genotyped for *pfhrp2/3*. Most of these (125/140) were found to be *pfhrp2+/pfhrp3+*, with smaller numbers deleted for only *pfhrp2* (n=9) or only *pfhrp3* (n=6). No dual *pfhrp2/3* deleted parasites 48 were observed. This survey estimated that 0.24% (95% confidence interval: 0.08% to 0.39%) of 49 50 false-negative HRP2-RDTs for symptomatic persons were due to pfhrp2 deletions in this 2021 51 Tanzania survey. These data provide evidence for HRP2-based diagnostics as currently 52 accurate for *P. falciparum* diagnosis in Tanzania.

53

54 **Keywords:** *Plasmodium falciparum*, Tanzania, RDT, *pfhrp2*, *pfhrp3*, gene deletion

#### 55 Introduction

56 Scaling-up of malaria control interventions since the year 2000 has resulted in dramatic 57 decreases in *Plasmodium falciparum* cases and deaths in sub-Saharan Africa [1, 2]. However, 58 due to disruption of services in the years 2020 and 2021 due to the SARS-CoV-2 pandemic, an 59 estimated 50,000 additional malaria deaths occurred during each of those years [1], showing 60 how gains from malaria control can guickly be lost. Malaria control efforts can take many 61 different forms, including (but not limited to) insecticide treated net distribution, accurate parasitological confirmation of *Plasmodium* infections, and effective case management by 62 provision of efficacious antimalarial drugs. Even these pillars of malaria control are being 63 64 threatened in sub-Saharan Africa through vector insecticide resistance [3, 4], P. falciparum 65 diagnostic resistance by pfhrp2 gene deletions [5-7], and emergence of antimalarial drug 66 resistance genotypes [8].

67 Use of antigen-detecting rapid diagnostic tests (RDTs) has been a pragmatic strategy for parasitological confirmation of *P. falciparum* infection through detection of *Plasmodium* 68 69 antigens, and has enabled better targeting of treatment and improved surveillance of malaria 70 [9]. The histidine-rich protein 2 (HRP2) antigen is a species-specific target for *P. falciparum*, though detection of the Plasmodium lactate dehydrogenase (LDH) antigen can also be a 71 72 reliable diagnostic marker - especially for higher parasite density infections typically seen in 73 clinical cases. RDT products have been developed which have capture/detection antibodies 74 which would bind any Plasmodium LDH (pan-Plasmodium), or the P. falciparum- and P. vivax-75 specific epitopes of this antigen [10]. Similar to the HRP2 antigen, HRP3 is expressed by P. 76 falciparum and can also supplement the detection signal for HRP2-based RDTs or other immunoassays [9, 11]. Given the predominance of *P. falciparum* for the clinical relevance and 77 78 malaria epidemiology in sub-Saharan Africa, HRP2-based RDTs are highly preferred because 79 of thermal stability, abundance of antigen target, high species specificity, and lower cost [12].

80 Deletions of the *pfhrp2* and *pfhrp3* (*pfhrp2/3*) genes from the *P. falciparum* genome have 81 now been observed in multiple African countries and pose a serious threat to the use of these 82 antigenic markers to reliably detect *P. falciparum* infection [5-7, 9]. Natural parasite populations 83 with pfhrp2/3 gene deletions were first reported in Peru in 2010 [13], but P. falciparum has since 84 been found with these gene deletions in many settings [6, 14], and has now been reported in 85 more than 35 countries [15]. The World Health Organization (WHO) has issued guidance on 86 investigating suspected false-negative RDT results due to pfhrp2/3 gene deletions in malaria 87 parasites and is encouraging a harmonised approach to mapping and reporting the deletions 88 [16, 17]. Based on these guidelines, each country should endeavour to establish the status and monitor gene deletion trends over time to see if re-assessment of national diagnostic strategy is 89 90 warranted when ≥5% of *P. falciparum* clinical infections are missed by HRP2-RDTs. In 91 Tanzania, previous reports have shown sporadic occurrence of *pfhrp2* gene deletions in multiple 92 locations, though at very low levels (<2.0%) [18, 19]. However, all Tanzanian studies reported 93 to-date have utilized sampling designs different from WHO recommendations for reporting of 94 nationwide gene deletion estimates. This current study provides the first national evaluation of 95 pfhrp2/3 gene deletions in the P. falciparum parasite population and provides baseline data for 96 future monitoring to establish the temporal and spatial trends of these deletions in the country. 97

## 98 Methods

## 99 Ethics

The study protocol was adopted from the WHO template [17] and submitted to the Tanzanian Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research (NIMR) for review and ethical approval. The protocol was also submitted for review and approval by the ethics committee of WHO in Geneva, Switzerland. All research participants were asked and provided individual consent (or assent for children aged 7-18 years of age) for their participation in the survey and biobanking for future research. For children

under the legal age of adulthood in Tanzania (<18 years), consent was obtained from a parent</li>
or guardian. An informed consent form was developed in English and translated in Kiswahili and
used to obtain consent both verbally and in writing from all participants. All participants agreed
and signed the consent or assent form or provided a thumbprint in conjunction with the
signature of an independent witness in case the study participant was illiterate. The project was
approved as a program evaluation activity and non-human subjects research by the U.S.
Centers for Disease Control and Prevention (CDC, project ID: 0900f3eb81f722fb).

113

## 114 Study design

The cross-sectional study which was undertaken as part of the ongoing project on the 115 116 molecular surveillance of malaria in Tanzania (MSMT)[20], conducted in collaboration with the 117 Tanzanian National Malaria Control Programme (NMCP), the President's Office, Regional 118 Administration, and Local Government authority (PO-RALG) and collaborators from USA 119 (Brown University, University of North Carolina and the CDC). Ten regions of Tanzania were 120 utilized and 100 health facilities (HF) were selected according to WHO protocol as enrolment 121 sites [21]: Dar es salaam, Dodoma, Kagera, Kilimanjaro, Manyara, Mara, Mtwara, Njombe, 122 Songwe and Tabora (Figure 1). At each HF (10 HFs from each region), patients presenting with 123 malaria-like illness were approached and to enrolled in this study after providing an informed 124 consent. Regardless of enrolment in this study, patients with malaria-like illness were provided 125 an RDT, and if positive, treated with appropriate antimalarial drugs according to Tanzania 126 national guidelines.

127

## 128 Patient enrollment and sample collection procedures

Inclusion criteria required patients to be aged 6 months and above, meeting case
 definition for suspected malaria (fever in the last 48 hrs or fever at presentation with axillary
 temperature ≥37.5°C and/or other malaria symptoms), and requirement to reside in the same

area as the health facility. Exclusion criteria included previous enrollment in the study, severe
malaria, or other severe illnesses. For each patient, finger prick blood was collected for
detection of malaria infection by RDTs and also for preparation of dried blood spots (DBS) on
Whatman 3 MM CHR filter papers (Cytiva, USA).

136 At enrollment, each patient was tested by two types of RDTs, with the first being the 137 HRP2/pan-LDH test used by the Tanzanian NMCP for routine diagnosis of malaria ("national 138 RDT", listed below) and the second was the *P. falciparum* LDH test donated by WHO for this survey ("research RDT"), the #C14RHG25, RapiGEN Inc. BIOCREDIT Malaria Ag Pf (Pf-pLDH), 139 140 Republic of Korea). At the time of the survey, the Tanzanian NMCP had three types of RDTs which were concurrently used in the country. They included SD Bioline Malaria Ag P.f/pan 141 (#05FK60, Standard Diagnostic Inc., India), CareStart Malaria HRP2/pLDH (#RMOM-02571, 142 143 AccessBio Inc., NJ, USA) and First Response Malaria Ag HRP2/pLDH Combo (#PI16FRC10s, 144 Premier Medical Corp. India). "RDT discordance" for this study was defined as a positive Pf-145 pLDH result, but a negative HRP2 band. 146 Sample size for this survey was based on WHO master protocol [21], with a simple 147 random sampling design effect of 1.5 accounting for potential deletions of the pfhrp2 gene. A 148 target of 37 patients with positive results by either of the two tests were enrolled from each HF for a total target size of 370 samples per region and 3,700 RDT positive persons for the whole 149

study [21]. All DBS samples (positive and negative by RDTs) were stored at the HFs at ambient
 temperature and later shipped to the NIMR Genomics Laboratory after the end of the survey for

storage at room temperature before shipping to the CDC in Atlanta, GA, USA for further

153 analysis.

154

## 155 Sample processing and multiplex bead assay

156To rehydrate blood samples for *Plasmodium* antigen detection, a 6mm filter paper punch157from each DBS (approximately 10 μL whole blood) was placed into 200 μL of elution buffer:

158 phosphate buffered saline (PBS, Sigma) pH 7.2, 0.3% Tween-20, 0.5% casein (ThermoFisher), 159 0.5% bovine serum albumin (BSA, Sigma), 0.5% polyvinyl alcohol (Sigma), 0.8% polyvinlypyrrolidine (Sigma), 0.02% sodium azide (Sigma), and 3 µg/mL of E. coli lysate (to 160 prevent nonspecific binding). This provided a 1:20 dilution of whole blood which was used as 161 162 the test sample for the bead-based multiplex immunoassay. 163 The bead-based multiplex assay for malaria antigen detection was performed as 164 described previously [22]. Magnetic microbeads (xMAP®, Luminex Corp., Austin, TX) were 165 covalently bound to antibodies for *Plasmodium* antigen capture by the Luminex antibody coupling kit according to manufacturer's instructions. Per 12.5x10<sup>6</sup> beads, antibody coupling 166 167 concentrations were: anti-pan-Plasmodium aldolase antibody (pAldolase, 12.5 µg, Abcam, 168 Cambridge, UK); anti-pan-Plasmodium LDH (pLDH, 12.5 µg, clone M1209063, Fitzgerald, 169 Acton, MA); anti-P. falciparum HRP2 (20 µg, clone MPFG-55A, ICLlabs, Portland, OR); anti-P. 170 falciparum LDH (20 µg, clone M1209062, Fitzgerald). Detection antibodies were also prepared 171 in advance by biotinylating (EZ-link Micro Sulfo-NHS-Biotinylation Kit, ThermoScientific, 172 Waltham, MA) according to manufacturer's instructions. Final prepared dilution of detection 173 antibodies was 1.0 mg/mL and for anti-malarial antigen specific antibodies as follows: pAldolase 174 (Abcam), LDH (1:1 antibody mixture of M1709Pv1 and M86550, Fitzgerald), HRP2 (1:1 antibody mixture of MPFG-55A and MPFM-55A, ICLlabs). All reagents were stored at 4°C until use in the 175 176 immunoassay. 177 For the antigen multiplex assay, reagents were diluted in buffer containing 0.1M PBS

(pH 7.2), 0.05% Tween-20, 0.5% BSA, and 0.02% sodium azide. Assay plates were affixed to a
handheld magnet (Luminex Corp) for wash steps and allowed one minute for bead
magnetization before evacuation of liquid and washing with 100 µL PBS/0.05% Tween-20. The
four bead regions were combined in dilution buffer (in a reagent trough) and pipetted onto a 96well assay plate (BioPlex Pro, BioRad, Hercules, CA) at a quantity of approximately 800
beads/region. Plates were washed twice, and 50 µL of controls (in duplicate) or samples (in

184 singlet) were pipetted into appropriate wells. Following 90-minute gentle shaking at room 185 temperature, protected from light, plates were washed three times. A mixture of detection 186 antibodies was prepared in dilution buffer (pAldolase at 1:2000, all others at 1:500) and 50 µL added to each well for a 45-minute incubation. After three washes, 50 µL of streptavidin-187 188 phycoerythrin (at 1:200, Invitrogen) was added for a 30-minute incubation. Plates were washed 189 three times, and 50 µL dilution buffer was added to each well for 30-minute incubation. Plates 190 were then washed once and beads resuspended in 100 µL PBS. After brief shaking, plates 191 were read on a MAGPIX machine (Luminex Corp) with a target of 50 beads per region. The 192 median fluorescence intensity (MFI) value was generated for all beads collected for each region by assay well. Subtraction of the assay signal from wells with dilution buffer blank provided the 193 194 MFI-background (MFI-bg) value used for analyses. Positive and negative controls were included 195 on each assay plate to ensure valid assay results

196

#### 197 Selection of samples for PET-PCR Plasmodium speciation and DNA quality control

198 Samples were initially selected for PET-PCR speciation and *pfhrp2/3* genotyping if they 199 had discordant results (point-of-care RDTs showed positivity for the Pf-pLDH band but a 200 negative HRP2 band). Based on laboratory multiplex antigen data, the second selection of samples for Plasmodium speciation by PET-PCR and *pfhrp2/3* genotyping was done based on 201 202 the relationship between the two pan-Plasmodium antigens (aldolase and LDH) and the HRP2 and/or HRP3 (HRP2/3) signal as described previously [22], or relationship between Pf-pLDH 203 204 and HRP2/3. Samples were selected if completely lacking an assay signal for HRP2/3 or if the 205 assay signal for HRP2/3 was atypically lower compared to the level of pAldolase, pLDH, or Pf-206 pLDH antigens.

207

#### 208 **DNA extraction and quantification from samples**

209 For samples selected for genotyping, total genomic DNA was extracted from DBS 210 samples (three 6mm punches per sample) using Tween-Chelex 100 (Bio-Rad Laboratories, 211 USA) extraction method as previously described with some modifications [23]. Briefly, the 212 punched DBS samples were incubated in 1 mL of 0.5% Tween-20 (Sigma) in PBS (Thermo 213 Fisher Scientific) overnight at room temperature, placed onto the shaker at low speed to release 214 parasite DNA from red blood cells, and briefly centrifuged. Tween-PBS was removed followed 215 by washing with 1 mL of 1X PBS and incubation at 40°C for 30 min. The samples were briefly centrifuged, PBS removed, and 150 µL of 10% Chelex 100 resin (BioRad) in water were added 216 to each sample and incubated for 10 min at 95°C. Supernatant was removed from the tubes 217 followed by addition of 1 mL PBS, briefly vortexed, and incubated at 4°C for 15-30 min. After a 218 219 brief centrifugation to precipitate the DNA from other impurities, a 2:1 solution of Chelex to 220 sterile water was added and incubated at 95°C for 10 min. Samples were centrifuged for 5 min 221 at high speed to pellet Chelex and filter paper and resulting DNA supernatants (approximately 222 150 µL) were transferred to new tubes. Supernatants were centrifuged for 10 min at 14,000 rpm, 223 and the Chelex-free supernatant (approximately 50 µL) was transferred to a new tube for storage at 20°C until use in PCR assays. 224

225

## 226 **PET-PCR and genotyping for** *P. falciparum pfhrp2* and *pfhrp3* genes

PET-PCR was performed on extracted DNA as described previously to ensure quality and presence of *P. falciparum* DNA [22]. Genotyping for *pfmsp1*, *pfmsp2*, and *pfhrp3* was performed by nested PCR (nPCR) as described previously [22]. For *pfhrp2* genotyping, conventional PCR was performed as described previously [24]. Results for *pfhrp2/3* genotyping were only reported if both *pfmsp1* and *pfmsp2* (both single-copy genes in the *P. falciparum* genome) were successfully amplified for a DNA sample in at least two out of three independent PCR reactions [16].

#### 235 Results

236 From February to July 2021, a total of 8,040 persons were enrolled among the 100 237 Tanzanian HFs (Figure 1) with a recorded RDT result and 7,863 persons (97.8%) providing 238 DBS for later laboratory assays. Of this set of DBS, 7,847 (99.8%) were able to be inventoried 239 and had laboratory multiplex antigen data collected. For all enrolled participants, median age was 15 (interguartile range: 3 to 29 years), and 55.3% were female (Table 1). Numbers of 240 241 participants enrolled among regions were similar except Kilimanjaro which enrolled 31.6% of all 242 patients: this was due to the very low transmission setting in Kilimaniaro region and need to 243 enroll more persons to obtain the target of 37 RDT positive persons per health facility [21]. RDT results found 48.2% (n=3,787) of all patients positive by any RDT utilized in the survey. For the 244 245 3,787 patients who showed a positive RDT result to any antigen target, 3,185 (84.1%) were 246 positive to both targets on the national RDT and 545 (14.4%) were positive only for the HRP2 247 band. The research RDT, testing only for Pf-pLDH, showed strong concordance with national 248 RDT results and 3,020 (79.7%) of persons positive by the research RDT also showed positivity by the national RDT. Of these 767 testing positive only by the national RDT, and not the 249 250 research RDT, the majority of these (n=609, 79.4%) were only HRP2 positive, indicating a 251 lower-density P. falciparum infection [25]. A total of 95 persons tested positive only by the 252 research RDT, representing discordance of 2.5% of the "any RDT" positives.

253 The DBS from these 95 persons testing positive by only Pf-pLDH were selected for 254 further PCR assays based on suspicion of *P. falciparum* infection with potential deletions in the 255 pfhrp2 (and pfhrp3) genes. Of these 95, nine DBS (9.5%) were unable to be retrieved, and an 256 additional 46 (48.4%) were negative for P. falciparum DNA, leaving 40 (42.1%) appropriate for 257 further *pfhrp2/3* genotyping. Additionally, DBS were also selected for further PCRs based on 258 results from the laboratory multiplex antigen detection assay. In comparing the laboratory-259 detected antigen levels of HRP2/3 versus other *Plasmodium* markers (assay signal for 260 pAldolase, pLDH, and Pf-pLDH), if a blood sample was positive for any *Plasmodium* antigen,

261 the vast majority of these were observed to have high levels of HRP2/3 relative to the other 262 three targets (Figure 2). From the lab multiplex antigen assay, a total of 135 specimens (1.7% 263 of the 7,847 DBS available; shown by red shading in Figure 2) were selected for DNA extraction 264 and further assays to determine pfhrp2/3 status of the infecting parasites. Of these 135, 118 (87.4%) were confirmed to have P. falciparum DNA to attempt the pfhrp2/3 genotyping PCRs 265 266 (Figure 3). Concordance of lab antigen positivity between the blood samples from the 95 267 persons testing RDT positive only for Pf-pLDH is shown in Supplemental Figure 1. 268 Approximately half (50/95, 52.6%) of the blood samples from these "RDT discordant" persons 269 positive for any *Plasmodium* antigen by the lab multiplex assay, and only 35.8% of these blood samples were positive by both the Pf-pLDH RDT and the Pf-pLDH lab assay. 270 271 Between the RDT discordant (n=40) and lab antigen assay (n=118) selection strategies, 272 a total of 137 P. falciparum infections were selected to move forward with pfhrp2/3 genotyping 273 (Figure 3). Most of these P. falciparum DNA positive samples (88.6%, 140/158) were also able 274 to amplify the single-copy genes (pfmsp1 and pfmsp2 in this study) required for quality 275 assurance reporting of pfhrp2/3 genotyping results. Of these 140, the majority (89.2%, 125/140) 276 were able to amplify both the *pfhfrp2* and *pfhrp3* genes (a *pfhrp2+/pfhrp3*+ genotype), six (4.3%) 277 showed a genotype of *pfhrp2+/pfhrp3*-, nine (6.4%) a *pfhrp2-/pfhrp3*+ genotype, and no 278 parasites from P. falciparum infections were found to have the double-deletion pfhrp2-/pfhrp3-279 genotype. All nine persons infected with P. falciparum with pfhrp2 deletions were negative on 280 the national RDT for the HRP2 band. P. falciparum infections with single gene deletions for pfhrp2 or pfhrp3 were found to be 281 282 largely dispersed throughout the country, though some clustering was observed in the southern

part of Njombe region (Figure 4). Due to the sampling design and rare finding of any deletions,

spatial inference was not attempted to denote statistically significant clustering patterns. The

nine infections containing *pfhrp2*-deleted *P. falciparum* were from: Dodoma (n=1), Kilimanjaro

284

286 (n=1), Manyara (n=2) regions in northeast Tanzania, the Njombe region in the south (n=4), and

287 Kagera region in the extreme northwest (n=1). The four *pfhrp2* deletions in Niombe were 288 enrolled at two health facilities with two infections with deleted parasites found in each. From 289 estimates reported in the year 2020 for *P. falciparum* transmission strata by region in Tanzania [26], the majority of the pfhrp2 deletions (8/9, 88.9%) were found in either "low" or "very low" 290 291 transmission strata (Supplemental Figure 2). The *pfhrp3*-deleted parasites were found in: Dar es 292 Salam region (n=1), Kagera region (n=2), infections from the same health facility), Njombe 293 region (n=2, infections from different health facilities), and Mbeya region (n=1). The only regions 294 to show parasites both having pfhrp2 or pfhrp3 deletions were Kagera and Njombe, and the 295 ones in Njombe were all noted in the far southern area of this region.

296

## 297 Discussion

298 Increasing global reports of deletions of the pfhrp2 (and to lesser extent pfhrp3) genes 299 have concerned malaria stakeholders in countries heavily relying on HRP2-based RDTs for 300 clinical diagnosis of *P. falciparum* infection [15, 22]. Enrolling of 7,863 malaria suspected 301 patients in 100 health facilities throughout Tanzania in 2021 who provided a DBS sample found 302 48.2% of persons with a positive RDT result with very few individuals (n=95, 2.5% of all RDT 303 positives) testing positive for the *P. falciparum* antigen Pf-pLDH, but negative for HRP2. Importantly, as all persons enrolled in this study were presenting with malaria-like symptoms, 304 305 from this RDT data alone it could be surmised that *P. falciparum* is the predominant species causing clinical malaria in Tanzania. The concordance in test results between the two 306 307 independent RDTs shows a low risk of infections with *P. falciparum* not producing high levels of 308 the HRP2/3 antigen(s) – as the phenotypic indicator of deleted or non-functional pfhrp2 (or 309 pfhrp3) genes [9, 13]. In assessing potential pfhrp2/3 deletions in Tanzania for this survey. 310 multiplex antigen screening including targets for HRP2 and other *Plasmodium* antigens allowed 311 a secondary approach to also compare with RDT results and elucidate *pfhrp2/3* deletions [18, 27]. Of 7,847 DBS assayed by the lab multiplex assay, only 1.7% (n=135) were selected for 312

313 further molecular assays based on the absence, or very low levels, of HRP2 antigen in the 314 blood sample relative to the other *Plasmodium* targets. The combination of these two 315 approaches (RDT concordance and lab multiplex antigen assay) both pointed to the same 316 phenotypic findings: the vast majority of clinical malaria in Tanzania is being caused by P. 317 falciparum producing sufficient HRP2/3 antigen to elicit positive HRP2-based RDT results. The 318 inclusion of *pfhrp2/3* genotyping data for these malaria patients enrolled throughout Tanzania 319 provides further evidence for the very low prevalence of P. falciparum parasites causing 320 symptomatic disease that would be missed by routine HRP2-based RDTs currently utilized in 321 Tanzania. When combining the antigen and genotyping data, it is estimated here that 0.24% (95% CI: 0.08-0.39%) of false-negative HRP2-RDTs were due to pfhrp2 deletions from this 322 323 survey.

324 Current recommendations provided by the WHO set a threshold of 5% or greater of 325 clinical *P. falciparum* infections evading HRP2 diagnostics as criteria to re-assess use of HRP2 326 as a standard diagnostic tool in a setting [17, 21]. For numerous practical reasons, malaria 327 diagnostic strategies are typically made at the national level, so national surveys would need to 328 be inclusive of *P. falciparum* endemic settings throughout a country to most appropriately 329 generate this quantitative estimate and compare to the 5% threshold. This survey design is 330 robust and provides opportunities not only for evaluation of *pfhrp2/3* deletion status in a country, 331 but also assessment of *P. falciparum* parasite diversity (including drug resistance and 332 population genetic markers), estimation of non-falciparum clinical burden, and other malaria 333 clinical comparisons and analyses [6, 28, 29]. From this 2021 Tanzania survey, reports outlining 334 findings for putative drug resistance markers and findings of non-falciparum malaria infections 335 are forthcoming.

Throughout the 100 health facilities where persons were enrolled in this survey, only twelve facilities enrolled persons with *P. falciparum* parasites showing any deletions: seven sites with infecting parasites lacking *pfhrp2*, and five sites with infecting parasites lacking *pfhrp3*.

339 Furthermore, these twelve sites were broadly spread out throughout the country and inclusive of 340 different sub-populations of *P. falciparum* strains [30]. The notable exception to this generalized 341 finding was the observation of four health facilities in southern Niombe region enrolling persons 342 with *P. falciparum* infections with *pfhrp2* or *pfhrp3* gene deletions. However, even within this 343 "cluster", of 180 persons enrolled among these three sites, 63% (n=113) were found to have P. 344 falciparum infections, meaning that only 3.5% (4/113) of identified P. falciparum infections 345 among these three sites showed *pfhrp2* single deletions. Importantly, deletions in the *pfhrp3* gene are not regarded for the WHO 5% *pfhrp2* deletion threshold as this gene product (HRP3) 346 is a truncated form of the HRP2 antigen and is not thought to contribute significantly to the RDT 347 348 test band intensity when both antigens are present [31]. To this point, all nine P. falciparum 349 infections identified in this current Tanzania study which had parasites deleted for *pfhrp2* had 350 produced a negative band result for HRP2 by RDT. Future studies may look to over-sample 351 from this area of the country to see if prevalence and diagnostic impact of pfhrp2/3 gene 352 deletions is truly higher here versus other regions. The results from this current study are 353 consistent with a previous 2017 Tanzania nationwide survey of border regions which enrolled 354 persons in their households. In this population of persons not actively seeking treatment, 32% of 355 persons were positive to any *Plasmodium* antigen targets, but no *pfhrp2/3* deletions were 356 observed [18]. However, these findings contrast to a 2018 health facility survey enrolling 357 persons in the Kilimanjaro and Tanga regions in the northeast part of the country which 358 estimated pfhrp2 deletions at 1.6% of P. falciparum infections and pfhrp3 deletions at 52% -359 though no dual deletions were observed [19]. Different sampling strategies, enrolment during 360 different transmission seasons, and laboratory assays may ultimately lead to differences in prevalence estimates for gene deletions, but results from this current study combined with the 361 362 previous two studies have consistently shown very low rates of *pfhrp2* deletions. 363 Though an overall low number of *pfhrp2* deletions were observed in this study, an

important finding was that nearly all of these (8/9, 88.9%) were discovered in the relatively lower

transmission central and southern regions of the country. This has been observed in previous *pfhrp2/3* deletion studies as well, with these deletion genotypes affecting RDT results relatively more when overall transmission and complexity of infections are reduced [32, 33]. As Tanzania moves towards malaria elimination in the future, reducing overall transmission and the number of *P. falciparum* strains in a patient at any one point in time may increase the risk for deletion genotypes to affect HRP2-RDT accuracy.

371 This study was subject to limitations which may affect estimates or interpretation of

372 results. Patient enrolment from February to July is mostly inclusive of the rainy season in

373 Tanzania, so prevalence of these deletions leading to false negative HRP2-RDT results during

dry season months was not evaluated here [32]. Though the survey was designed to be

375 geographically-representative, persons were only enrolled from 10 of the 26 regions in mainland

376 Tanzania, meaning large areas and *P. falciparum* sub-populations have not been sampled.

377 *P. falciparum* infections from persons enrolled in 2021 were largely positive for the

378 *pfhrp2/3* genes and produced high levels of the HRP2 antigen to elicit true positive HRP2-RDT

379 results. From evidence generated here, the HRP2 antigen still appears to be a robust tool for

identification of *P. falciparum* infection in Tanzania. As these gene-deleted parasites may have

a selective advantage over their wild-type counterparts, or potentially be imported, future efforts

382 should continue to monitor for HRP2-RDT validity in the country.

383

### 384 **References**

1. World Health Organization. World malaria report 2021. Geneva, Switzerland, **2021**.

386 2. Gething PW, Casey DC, Weiss DJ, et al. Mapping Plasmodium falciparum Mortality in Africa between
 387 1990 and 2015. N Engl J Med **2016**; 375:2435-45.

388 3. Keita M, Sogoba N, Kane F, et al. Multiple Resistance Mechanisms to Pyrethroids Insecticides in

Anopheles gambiae sensu lato Population From Mali, West Africa. J Infect Dis **2021**; 223:S81-S90.

390 4. Matowo NS, Martin J, Kulkarni MA, et al. An increasing role of pyrethroid-resistant Anopheles

funestus in malaria transmission in the Lake Zone, Tanzania. Sci Rep **2021**; 11:13457.

- 392 5. Berhane A, Anderson K, Mihreteab S, et al. Major Threat to Malaria Control Programs by Plasmodium
- falciparum Lacking Histidine-Rich Protein 2, Eritrea. Emerg Infect Dis **2018**; 24:462-70.

- Feleke SM, Reichert EN, Mohammed H, et al. Plasmodium falciparum is evolving to escape malaria
   rapid diagnostic tests in Ethiopia. Nat Microbiol **2021**; 6:1289-99.
- 396 7. Iriart X, Menard S, Chauvin P, et al. Misdiagnosis of imported falciparum malaria from African areas
- due to an increased prevalence of pfhrp2/pfhrp3 gene deletion: the Djibouti case. Emerg Microbes
   Infect 2020; 9:1984-7.
- 399 8. Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H
- 400 genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre,
- 401 therapeutic efficacy study. Lancet Infect Dis **2021**; 21:1120-8.
- 9. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria Diagnosis, but with
  Caveats. Trends Parasitol **2020**; 36:112-26.
- 404 10. World Health Organizaion. Malaria rapid diagnostic test performance. Results of WHO product
   405 testing of malaria RDTs: Round 8 (2016-2018). Geneva, Switzerland, 2018.
- 406 11. Plucinski M, Aidoo M, Rogier E. Laboratory Detection of Malaria Antigens: a Strong Tool for Malaria
  407 Research, Diagnosis, and Epidemiology. Clin Microbiol Rev **2021**; 34:e0025020.
- 408 12. Boyce MR, O'Meara WP. Use of malaria RDTs in various health contexts across sub-Saharan Africa: a 409 systematic review. BMC Public Health **2017**; 17:470.
- 410 13. Gamboa D, Ho MF, Bendezu J, et al. A large proportion of P. falciparum isolates in the Amazon region
- 411 of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One **2010**; 5:e8091.
- 412 14. Akinyi Okoth S, Abdallah JF, Ceron N, et al. Variation in Plasmodium falciparum Histidine-Rich Protein
- 413 2 (Pfhrp2) and Plasmodium falciparum Histidine-Rich Protein 3 (Pfhrp3) Gene Deletions in Guyana and
- 414 Suriname. PLoS One **2015**; 10:e0126805.
- 415 15. Thomson R, Parr JB, Cheng Q, Chenet S, Perkins M, Cunningham J. Prevalence of Plasmodium
- falciparum lacking histidine-rich proteins 2 and 3: a systematic review. Bull World Health Organ 2020;
  98:558-68F.
- 418 16. Cheng Q, Gatton ML, Barnwell J, et al. Plasmodium falciparum parasites lacking histidine-rich protein
- 419 2 and 3: a review and recommendations for accurate reporting. Malar J **2014**; 13:283.
- 420 17. World Health Organization. Response plan to pfhrp2 gene deletions. Geneva, Switzerland, **2019**.
- 421 18. Bakari C, Jones S, Subramaniam G, et al. Community-based surveys for Plasmodium falciparum
- 422 pfhrp2 and pfhrp3 gene deletions in selected regions of mainland Tanzania. Malar J **2020**; 19:391.
- 423 19. Kaaya RD, Kavishe RA, Tenu FF, et al. Deletions of the Plasmodium falciparum histidine-rich protein
- 424 2/3 genes are common in field isolates from north-eastern Tanzania. Sci Rep **2022**; 12:5802.
- 425 20. Lyimo BM, Popkin-Hall ZR, Giesbrecht DJ, et al. Potential Opportunities and Challenges of Deploying
- 426 Next Generation Sequencing and CRISPR-Cas Systems to Support Diagnostics and Surveillance Towards
- 427 Malaria Control and Elimination in Africa. Front Cell Infect Microbiol **2022**; 12:757844.
- 428 21. World Health Organization. Master protocol for surveillance of pfhrp2/3 deletions and biobanking to 429 support future research. Geneva, Switzerland, **2020**.
- 430 22. Rogier E, McCaffery JN, Nace D, et al. Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions
- 431 from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda. Emerg
  432 Infect Dis **2022**; 28:608-16.
- 433 23. Teyssier NB, Chen A, Duarte EM, Sit R, Greenhouse B, Tessema SK. Optimization of whole-genome
- 434 sequencing of Plasmodium falciparum from low-density dried blood spot samples. Malar J **2021**; 20:116.
- 435 24. Jones S, Subramaniam G, Plucinski MM, et al. One-step PCR: A novel protocol for determination of
- 436 pfhrp2 deletion status in Plasmodium falciparum. PLoS One **2020**; 15:e0236369.
- 437 25. Rogier E, Bakari C, Mandara Cl, et al. Performance of antigen detection for HRP2-based malaria rapid
- diagnostic tests in community surveys: Tanzania, July-November 2017. Malar J **2022**; 21:361.
- 439 26. Thawer SG, Chacky F, Runge M, et al. Sub-national stratification of malaria risk in mainland Tanzania:
- a simplified assembly of survey and routine data. Malar J **2020**; 19:177.

- 441 27. Plucinski MM, Herman C, Jones S, et al. Screening for Pfhrp2/3-Deleted Plasmodium falciparum,
- 442 Non-falciparum, and Low-Density Malaria Infections by a Multiplex Antigen Assay. J Infect Dis 2019;
  443 219:437-47.
- 444 28. Abuaku B, Amoah LE, Peprah NY, et al. Malaria parasitaemia and mRDT diagnostic performances
- among symptomatic individuals in selected health care facilities across Ghana. BMC Public Health 2021;
  21:239.
- 447 29. Amoah LE, Abuaku B, Bukari AH, et al. Contribution of P. falciparum parasites with Pfhrp 2 gene
- deletions to false negative PfHRP 2 based malaria RDT results in Ghana: A nationwide study of
- symptomatic malaria patients. PLoS One **2020**; 15:e0238749.
- 450 30. Moser KA, Madebe RA, Aydemir O, et al. Describing the current status of Plasmodium falciparum
- 451 population structure and drug resistance within mainland Tanzania using molecular inversion probes.
  452 Mol Ecol **2021**; 30:100-13.
- 453 31. Kong A, Wilson SA, Ah Y, Nace D, Rogier E, Aidoo M. HRP2 and HRP3 cross-reactivity and implications
- 454 for HRP2-based RDT use in regions with Plasmodium falciparum hrp2 gene deletions. Malar J **2021**;
  455 20:207.
- 456 32. Kozycki CT, Umulisa N, Rulisa S, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact
- of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission. Malar J **2017**;
  16:123.
- 459 33. Molina-de la Fuente I, Benito MJS, Flevaud L, et al. Plasmodium falciparum pfhrp2 and pfhrp3 Gene
- 460 Deletions in Malaria-Hyperendemic Region, South Sudan. Emerg Infect Dis **2023**; 29:154-9.
- 461

## 462 Acknowledgements

463 The authors acknowledge the contribution of the following project staff who participated in data

- 464 collection and/or laboratory processing of samples; Ruth B. Mbwambo, Ramadhani Moshi,
- 465 Dativa Pereus, Doris Mbata, Ezekiel Malecela, Muhidin Kassim, August Nyaki, Juma Tupa,
- 466 Idephonce Mathias, Godbless Msaki, Rashid Mtumba, Gasper Lugela, Francis Chambo, Neema
- 467 Barua, Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusa and Tilaus Gustav.
- The finance, administrative and logistic support team at NIMR: Christopher D. Masaka, Millen A.
- 469 Meena, Beatrice Mwampeta, Gracia L. Sanga, Neema Manumbu, Halfan Mwanga, Arison
- 470 Ekoni, Twalipo Mponzi, Pendael Nasary, Denis Byakuzana, Emmanuel Mnzava, Seth Nguhu,
- 471 Thomas Semdoe and Andrea Kimboi. Management of the National Institute for Medical
- 472 Research, National Malaria Control Program and Presidents Office-Regional Administration and
- 473 Local Government (Regional administrative secretaries of the 10 regions, and district officials
- 474 and staff from all 100 HFs. Technical and logistics support from the Bill and Melinda Gates
- 475 Foundation team; Philip Welkhoff, Jennifer Gardy, Estee Torok, Sevreina Smith, Janice

- 476 Culpepper, Lucy Hoffen, Maliha Anwar and Rosalyn Yearly. This study was funded by the Bill
- 477 and Melinda Gates Foundation (Inv. No. 002202).
- 479 Disclaimer
- 480 The findings and conclusions in this report are those of the author(s) and do not necessarily
- represent the official position of the Centers for Disease Control and Prevention and the Bill and
- 482 Melinda Gates Foundation.

- ....

## 502 Tables

#### 

# **Table 1. Demographic and RDT characteristics of enrolled patients: Tanzania 2021.**

Region	Provided RDT and DBS (n, % of all)	Median age (years, IQR)	Female (n, %)	RDT positive (n, %)	RDT Discordant* (n, % of RDT positives)
Kagera	619 (7.9)	6 (2-17)	326 (52.7)	378 (61.1)	15 (4.0)
Dar es Salaam	591 (7.5)	21 (5-29)	303 (51.3)	373 (63.1)	4 (1.1)
Dodoma	694 (8.8)	13 (3-30)	368 (53.0)	379 (54.6)	8 (2.1)
Kiimanjaro	2,484 (31.6)	21 (6-39)	1,449 (58.3)	381 (15.3)	10 (2.6)
Tabora	532 (6.8)	3 (2-11)	287 (53.9)	379 (71.2)	7 (1.8)
Songwe	594 (7.6)	12 (3-26)	337 (56.7)	378 (63.6)	14 (3.7)
Njombe	605 (7.7)	17 (7-30)	348 (57.5)	381 (63)	10 (2.6)
Mtwara	598 (7.6)	5 (3-20)	348 (58.2)	389 (65.1)	3 (0.8)
Manyara	574 (7.3)	18 (6-29)	268 (46.7)	376 (65.5)	9 (2.4)
Mara	572 (7.3)	8 (3-21)	318 (55.6)	373 (65.2)	15 (4.0)
Total	7,863	15 (3-29)	4,352 (55.3)	3,787 (48.2)	95 (2.5)

\* Positive Pf-pLDH band and negative HRP2 band

IQR: interquartile range; RDT: rapid diagnostic test; HRP2: histidine-rich protein 2; pLDH: pan-*Plasmodium* lactate dehydrogenase; DBS: dried blood spot

# 518 Figures

#### 





**involved in the survey: Tanzania 2021.** Individual health facilities are shown by red triangles.





530 *Plasmodium* antigens. Scatterplots represent data from all 7,847 DBS which were assayed by

531 bead-based multiplex assay for *Plasmodium* antigens. Antigen levels for HRP2/3 versus PfLDH

532 (A), pAldolase (B), and pLDH (C). Red shading indicates DBS with depressed or absent

533 HRP2/3 levels selected for subsequent *pfhrp2* and *pfhrp3* genotyping.



535

536 Figure 3. Flow diagram for selection of specimens for genotyping of *pfhrp2* and *pfhrp3* 

with results: Tanzania, 2021. Selection strategy included consideration of laboratory antigen

detection assay (on left), and RDT result at point-of-contact (on right). Terminal boxes display

- *pfhrp2* and *pfhrp3* deletion genotypes for samples passing all quality steps.
- 540
- 541
- 542
- 543



545



547 deletions in *pfhrp2* or *pfhrp3*: Tanzania: 2021. Regions that were sampled from are named

548 on the map, with an 'X' indicating location of sample identified with *pfhrp2* deletion (n=9) and

- 549 solid '•' indicating sample identified with *pfhrp3* deletion (n=6). A number in parentheses
- indicates multiple deletions found at a single site. 550